GT Biopharma(GTBP) - 2021 Q3 - Quarterly Report

For the transition period from _____ to _____. GT BIOPHARMA, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-40023 For the quarterly period ended September 30, 2021. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 (State or other jurisdiction of incorporation or organization) Delaware 94-1620407 (I.R.S. Employer ...